- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- carboplatin, docetaxel, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 686
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- NY-ESO-1 OLP4, NY-ESO-1 OLP4 + Montanide, NY-ESO-1 OLP4 + Montanide + Poly-ICLC
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Buffalo, New York • New York, New York
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
- Interventions
- Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 5
- States / cities
- Conroe, Texas • Houston, Texas • League City, Texas + 1 more
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
- Interventions
- Alisertib, Paclitaxel
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- The Bronx, New York • Philadelphia, Pennsylvania • Houston, Texas + 1 more
- Conditions
- Breast Carcinoma, Deleterious CDH1 Gene Mutation, Deleterious DICER1 Gene Mutation, Deleterious SMARCA4 Gene Mutation, Deleterious STK11 Gene Mutation, Endometrial Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- Interview, Questionnaire Administration, Survey Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Houston, Texas
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Stage 3 Cancer, Stage 4 Cancer
- Interventions
- Bevacizumab, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreas Cancer, Colorectal Cancer, Endometrial Cancer, Prostate Cancer
- Interventions
- Relational Agent (RA), Enhanced Usual Care (EUC)
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Prolanta, a human prolactin receptor antagonist
- Biological
- Lead sponsor
- Oncolix, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod
- Drug · Biological
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2025
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Interventions
- D4064A
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
- Interventions
- Olvi-Vec, Platinum-doublet with or without bevacizumab
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Newport Beach, California • Orlando, Florida
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Organ Tumors
- Interventions
- Not listed
- Lead sponsor
- Precision Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Oakland, California • Boynton Beach, Florida + 19 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Aspirin 325mg, Placebo
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Portland, Oregon • Charlottesville, Virginia + 1 more
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Drug
- Lead sponsor
- Shattuck Labs, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Duarte, California • Chicago, Illinois + 2 more
- Conditions
- Ovarian Cancer, Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Cancer, PARP Inhibitor, Fatigue Related to Cancer Treatment, Fatigue in Cancer Survivors
- Interventions
- REVITALIZE Intervention, Educational Materials
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boulder, Colorado • Boston, Massachusetts + 1 more
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Placebo, Gemcitabine, Pertuzumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 32 more
- Conditions
- Ovarian Cancer, Ovarian Neoplasm
- Interventions
- Veliparib, Paclitaxel, Carboplatin, Placebo to Veliparib
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more
- Conditions
- Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- niraparib, pembrolizumab
- Drug · Biological
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- oregovomab
- Biological
- Lead sponsor
- AltaRex
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 29
- States / cities
- Berkeley, California • Los Angeles, California • Orange, California + 25 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- RAD001, bevacizumab
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
- Interventions
- Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 11
- States / cities
- Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 8 more
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Breast Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Serous Adenocarcinoma, Refractory Primary Peritoneal Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable High Grade Fallopian Tube Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Olaparib, Onalespib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more